cDC1s are crucial for anti-cancer immunity, and their abundance within tumors is associated with CD8+ T cell-mediated immune rejection, favorable overall patient survival, and better clinical response to immunotherapy (21, 22). The gene discussed is CD8A; the disease is cancer.